Anagenics Limited · ASX:AN1
Anagenics — Cellmid — Merger or Acquisition (September 2021)
21 slides from Anagenics's merger presentation, Sep 27, 2021
Slide 1: ASX Announcement: Cellmid Investor Webinar
ASX ANNOUNCEMENT CELLMID INVESTOR WEBINAR SYDNEY, Monday, 27 September 2021: Cellmid Limited (ASX: CDY) (‘Cellmid’ or ‘the Company’) advises that it will hold a webinar on Wednesday, 29 September 2021 at 11:00am Australian Eastern Standard Time. During the webinar Cellmid CEO Maria Halasz will prese
Slide 2: Creating a leading anti-aging health and beauty tech company
27 September 2021 ASX: CDY Creating a leading anti-aging health and beauty tech company 1
Slide 3: Forward looking statements
Forward looking statements This presentation has been prepared by Cellmid Limited ACN 111 304 119 (CDY or Company) for information purposes only. The presentation may contain forward- looking statements that are not guarantees of future performance and are subject to risks and uncertainties. Such fo
Slide 4: Agenda
Agenda ● Executive Summary ● Overview of BLC Cosmetics ● Overview of Cellmid ● Transaction Overview ● Board and Management ● FY2022 and Beyond ● ESG Statement 3
Slide 5: Executive Summary
Executive Summary Acquisition BLC Strategic Overview Cosmetics Rationale ● Cellmid signed a share sale agreement with ● BLC is wholly owned by HGL Limited, a ● Scale in market with doubling of Cellmid’s HGL Limited (ASX:HNG) (HGL), to acquire diversified investment company FY2021 revenue and other i
Slide 6: Executive Summary
Executive Summary Board and Financial Timing Management Outcomes ● HGL will nominate a Non-Executive ● Cellmid will hold a meeting of shareholders ● Combined group revenue exceeding $13M Director to the Cellmid Board on 22 October 2021 to approve the issuing based on 30 June 2021 unaudited of 32,786
Slide 7: Overview of BLC Cosmetics
Overview of BLC Cosmetics FY2021 FY2021 11 900+ 8 Revenue EBITDA $7M* $500K* Premium Distribution Sales team in Up 20% on pcp Up 155% on pcp brands points including Aus and NZ DTC online 6
Slide 8: BLC: Revenue Growth
BLC: Revenue Growth Revenue: FY2019 – FY2021F* Revenue growth was driven by new brands and increased online sales, despite lockdown impacts during the year 7
Slide 9: BLC: Earnings Growth
BLC: Earnings Growth EBITDA: FY2019 – FY2021F* 8
Slide 10: Overview of Cellmid
Overview of Cellmid Addressing the rapidly A health and beauty-tech business growing growing global demand for shareholder value through the global distribution and sales of its proprietary, scientifically validated functional, high performing innovative consumer products in anti-aging and health an
Slide 11: Cellmid - Strong Growth Until COVID-19 Disruption
Cellmid - Strong Growth Until COVID-19 Disruption FY2016 / FY2019 - Strong revenue growth • Expansion of distribution channels across Japan, China, US, Australia, Asia and Europe Revenue $m • Prestige positioning of évolis® in the US through bricks and mortar stores (Neiman Marcus, Bloomingdales) •
Slide 12: Transaction Overview
Transaction Overview Cellmid may also pay a second tranche, based on an Cellmid and BLC Cosmetics signed a share sale increase in BLC’s audited FY2022 organic EBITDA; the agreement with HGL to acquire 100% of the shares in second tranche will be calculated as 3 x the incremental BLC Cosmetics Pty Lt
Slide 13: Strategic Rationale of BLC Acquisition
Strategic Rationale of BLC Acquisition • with doubling of Cellmid’s Acquisition to create an FY2021 revenue and other income of $7.3M innovative • Combined pro forma annualised revenue post merger of as of 30 June 2021, already growing through with a global organic products and channels distribution
Slide 14: Combined Pro-forma Profit and Loss Statement
Combined Pro-forma Profit and Loss Statement as of 30 June 2021 Organic growth: CDY and BLC are expected to grow organically in FY2022 in addition to the synergies identified Synergies: Synergies are expected to result in revenue growth PLUS cost savings improving profitability Combined result: The
Slide 15: Building Scale: Pro-forma Financial Position
Building Scale: Pro-forma Financial Position* 14
Slide 16: Building Scale: Pro-forma Financial Position
Building Scale: Pro-forma Financial Position* 15
Slide 17: Growth Opportunities
Growth Opportunities Expand in China: Increase market penetration and New e-commerce platforms Increase export of heritage sales in China through recently launched progressively from brands from Japan to other Asian signed distribution agreements, June 2021, grow recurring markets, increase Japanese
Slide 18: Experienced Board & Management Team
Experienced Board & Management Team Bruce Gordon | Chairman Maria Halasz | CEO and Managing Director Audit, Financial Management, Governance Strategy, Leadership, Corporate Finance, Innovation, Governance Dennis Eck | Non-Executive Director Dr Martin Cross | Non-Executive Director Strategy, Consumer
Slide 19: FY2022 Outlook
FY2022 Outlook COVID-19: Store and salon sales are likely to : Building the Jo-Ju and continue to be affected in the first With a 1 October 2021 effective evolis brands with CDY’s distribution half of FY2022 in Australia, but settlement date CDY will benefit from three quarters of BLC sales in partn
Slide 20: Driven By Environmental, Social & Governance Principles
Driven By Environmental, Social & Governance Principles • We encourage diversity and respect of all sexes, races, religions and cultures amongst our employees, suppliers, customers and other stakeholders • We are committed to providing high quality, effective and ethical products to our customers •
Slide 21: Thank You
THANK YOU Maria Halasz | CEO info@cellmid.com.au +61 9221 6830 20